NL-OMON47510
Recruiting
Not Applicable
The effect of Glucocorticoid Receptor Polymorphisms and Metabolically Active Genetic Variants on Glucose Metabolism in the Skeletal Muscle - GR polymorphisms, metabolic genetic variants and insulin resistance
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- diabetes
- Sponsor
- niversiteit Maastricht
- Enrollment
- 447
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects selected from studies 09\-3\-033; 07\-3\-028; 04\-257; 03\-015; 06\-3\-038;
- •09\-3\-039; 11\-3\-092; 11\-2\-003; 13\-3\-058; 13\-2\-030; 15\-3\-030; 113003; 153046;
- •163019; 163052; 173008; 173017; 173021; 173024; 173031; 173037; 183001 and
- •183006 (n\=447\).
Exclusion Criteria
- •NA, these already have been set by the previous studies.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study to assess whether a product call relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo.Endogenous Cushing syndromeMedDRA version: 20.0 Level: LLT Classification code 10011657 Term: Cushings syndrome System Organ Class: 100000004860Therapeutic area: Body processes [G] - Physiological processes [G07]EUCTR2018-003096-35-ESCorcept Therapeutics Incorporated130
Active, not recruiting
Phase 1
A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo.Endogenous Cushing syndromeMedDRA version: 24.0Level: LLTClassification code 10011657Term: Cushings syndromeSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Body processes [G] - Physiological processes [G07]EUCTR2018-003096-35-NLCorcept Therapeutics Incorporated162
Active, not recruiting
Phase 1
A study to assess whether relacorilant works and is safe to use in patients with Hypercortisolism due to Cortisol-Secreting Adrenal Adenomas or Hyperplasia; some patients will receive relacorilant whilst others receive a placebo.hypercortisolismMedDRA version: 22.1Level: LLTClassification code 10020611Term: HypercortisolismSystem Organ Class: 100000004860Therapeutic area: Body processes [G] - Physiological processes [G07]EUCTR2019-004956-12-ITCORCEPT THERAPEUTICS130
Completed
Phase 3
Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of RelacorilantCushing's syndrome10001353NL-OMON54706Corcept Therapeutics Incorporated4
Active, not recruiting
Phase 1
A study to assess whether a product called relacorilant works and is safe to use in patients with Cushing Syndrome; some patients will receive relacorilant whilst others receive a placebo.Endogenous Cushing syndromeMedDRA version: 24.0Level: LLTClassification code 10011657Term: Cushings syndromeSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Body processes [G] - Physiological processes [G07]EUCTR2018-003096-35-PLCorcept Therapeutics Incorporated162